{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-045844","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2026-10-06T11:30:06+00:00","discovered_at":"2026-10-06T11:35:00.308558+00:00","generated_at":"2026-10-12T16:36:23.164678+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kairos Pharma reports ENV-105 plus apalutamide median PFS of 17.7 months vs 2 months in Phase 2 mCRPC trial (P=0.0008)","bullets":["Interim Phase 2 analysis showed a statistically significant PFS difference for ENV-105 plus apalutamide vs apalutamide alone (median 17.7 vs 2 months; P=0.0008).","Kairos modified the Phase 2 protocol to enroll patients earlier, after PSA increase on an androgen signaling inhibitor, randomized to enzalutamide alone or with ENV-105.","The company targets completion of the Phase 2 trial in or before Q4 2027; CEO John Yu called the interim results an important clinical signal for ENV-105.","Patients were enrolled at Cedars-Sinai Medical Center, City of Hope and Huntsman Cancer Institute at the University of Utah.","ENV-105 (carotuximab) targets CD105, which Kairos describes as a key driver of resistance and relapse after standard cancer therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-045844","json":"https://secwatch.observer/filing/0001493152-26-045844.json","markdown":"https://secwatch.observer/filing/0001493152-26-045844.md","text":"https://secwatch.observer/filing/0001493152-26-045844.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000149315226045844/0001493152-26-045844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000149315226045844/form8-k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T16:36:23.164678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}